

Circulating CD34-Positive Cells Provide an Index of Cerebrovascular Function

Akihiko Taguchi, MD; Tomohiro Matsuyama, MD; Hiroshi Moriwaki, MD; Takuya Hayashi, MD; Kohei Hayashida, MD; Kazuyuki Nagatsuka, MD; Kenichi Todo, MD; Katsushi Mori; David M. Stern, MD; Toshihiro Soma, MD; Hiroaki Naritomi, MD

Background—Increasing evidence points to a role for circulating endothelial progenitor cells, including populations of CD34- and CD133-positive cells present in peripheral blood, in maintenance of the vasculature and neovascularization. Immature populations, including CD34-positive cells, have been shown to contribute to vascular homeostasis, not only as a pool of endothelial progenitor cells but also as a source of growth/angiogenesis factors at ischemic loci. We hypothesized that diminished numbers of circulating immature cells might impair such physiological and reparative processes, potentially contributing to cerebrovascular dysfunction.

Methods and Results—The level of circulating immature cells, CD34-, CD133-, CD117-, and CD135-positive cells, in patients with a history of atherothrombotic cerebral ischemic events was analyzed to assess possible correlations with the degree of carotid atherosclerosis and number of cerebral infarctions. There was a strong inverse correlation between numbers of circulating CD34- and CD133-positive cells and cerebral infarction. In contrast, there was no correlation between the degree of atherosclerosis and populations of circulating immature cells. Analysis of patients with cerebral artery occlusion revealed a significant positive correlation between circulating CD34- and CD133-positive cells and regional blood flow in areas of chronic hypoperfusion.

Conclusions—These results suggest a possible contribution of circulating CD34- and CD133-positive cells in maintenance of the cerebral circulation in settings of ischemic stress. Our data demonstrate the utility of a simple and precise method to quantify circulating CD34-positive cells, the latter providing a marker of cerebrovascular function. (*Circulation*. 2004;109:2972-2975.)

Key Words: cerebral infarction ■ cerebral ischemia ■ antigens, CD34 ■ stem cells

Although it had traditionally been assumed that replacement of damaged endothelium resulted only from outgrowth of preexisting vasculature, recent studies have identified endothelial progenitor cells (EPCs) that appear to contribute to vascular homeostasis and repair.¹ Clinical trials to assess the therapeutic potential of bone marrow-derived mononuclear cells, a rich source of immature cells including EPCs, in hind-limb^{2,3} and cardiac ischemia⁴ have been initiated and have, thus far, provided promising results. Furthermore, immature cells, including CD34-positive (CD34⁺) cells, have been shown to contribute to maintenance of the vasculature, not only as a pool of EPCs but also as the source of growth/angiogenesis factors.⁵ Bone marrow-derived immature cells have also been shown to participate in neovascularization of ischemic brain after experimental stroke.⁶ On the basis of these results, we hypothesized that levels of circulating immature cells might be proportional to

the resilience of the cerebral circulation to ischemic stress; ie, lower numbers of circulating immature cells might be associated with cerebral ischemia and infarction.

Methods

The institutional review board of the National Cardiovascular Center approved this study. All subjects provided informed consent. Circulating CD34⁺ cells in 50 μ L of peripheral blood were quantified according to the manufacturer's protocol (ProCOUNT, Becton Dickinson Biosciences). To minimize intersample variation for measurements of CD34⁺ cells, several methods were used: A nucleic acid dye was added as a threshold reagent; a no-wash technique was performed to eliminate cell loss, and reverse pipetting was used; an internal reference particle was added for determination of absolute cell numbers; and an isotype control, matched for the concentration of anti-CD34 antibody and fluorochrome-to-protein ratio, was included. All measurements were performed in triplicate (Figure 1A, control; Figure 1B, CD34). To quantify other stem cell populations (besides CD34⁺ cells), immature mononuclear cells were enriched

Received December 8, 2003; de novo received April 12, 2004; accepted May 11, 2004.

From the Departments of Cerebrovascular Disease (A.T., H.M., K.N., K.T., H.N.), Radiology and Nuclear Medicine (T.H., K.H.), and Clinical Physiology (K.M.), National Cardiovascular Center, Osaka, Japan; Department of Internal Medicine (T.M.), Hyogo College of Medicine, Hyogo, Japan; Dean's Office (D.M.S.), Medical College of Georgia, Augusta, Ga; and Department of Hematology (T.S.), Osaka Minami National Hospital, Osaka, Japan.

Correspondence to Akihiko Taguchi, Department of Cerebrovascular Disease, National Cardiovascular Center, 5-7-1 Fujishiro-dai, Suita, Osaka, 565-8565 Japan. E-mail ataguchi@res.ncvc.go.jp

© 2004 American Heart Association, Inc.

Circulation is available at <http://www.circulationaha.org>

DOI: 10.1161/01.CIR.0000133311.25587.DE




Figure 1. Quantification of circulating immature cells in patients with stroke. Nucleic acid dye versus CD34 PE dot plot was gated on lymphocytes and CD45 dim leukocytes. A, Results with an isotype-matched control antibody. B, Results with anti-CD34 antibody. Enriched immature mononuclear cells were double stained with PerCP-conjugated CD34 antibody (D) and PE-conjugated CD133 (F), CD117 (G), or CD135 (H) antibody. The number of cells in a region including brightly stained cells was counted. C and E, Staining with isotype nonimmune control antibody.

from 2 mL of peripheral blood by antibody-mediated depletion of mature cells according to the manufacturer's protocol (StemCell Technologies) using depletion cocktail, including antibodies to CD2, CD3, CD14, CD16, CD19, CD24, CD56, and CD66b. Enriched immature mononuclear cells were double-stained with peridinin chlorophyll protein (PerCP)-conjugated CD34 antibody (Figure 1D) and phycoerythrin (PE)-conjugated CD133 (Figure 1F), CD117 (Figure 1G), or CD135 (Figure 1H) antibody. The number of cells in a region including brightly stained cells was counted, and immature cells were quantified using CD34⁺ cells as an internal control. The cumulative intra-assay coefficient of variation was 14%, 13%, 14%, and 15%, with CD34⁺, CD133⁺, CD117⁺, and CD135⁺ cell measurements, respectively, from 5 stroke patients.

Atherosclerosis in the common and internal carotid arteries was analyzed by ultrasonography to determine plaque score as described previously.⁷ Cerebral infarcts (diameter >5 mm) were counted independently by a neurologist blinded to other parameters under study (number of circulating CD34⁺, etc) using T1-weighted, T2-weighted, and fluid-attenuated inversion-recovery MRI obtained with a 1.5-Tesla MRI scanner. The diagnosis of hypoperfusion was made angiographically. Regional cerebral blood flow (CBF), cerebral blood volume, oxygen extraction fraction (OEF), and cerebral metabolic rate of oxygen (CMRO₂) were quantified by conventional steady-state ¹⁵O PET using a PET scanner (Shimadzu) as described.⁸ Cerebrovascular function was evaluated in patients with chronic hypoperfusion caused by major cerebral artery (carotid artery or M1 portion of the middle cerebral artery) occlusion or severe stenoses (>90%) without a major stroke. Twelve patients with 15 major arterial occlusions or stenoses had PET examinations.

To investigate the mobilization of immature cells after acute cerebral infarction, peripheral blood was quantified at 6 hours and 3, 7, 14, and 30 days after the onset of stroke. The episodes of acute cerebral infarction were confirmed by the diffusion image of brain MRI. Age-matched volunteers who had no history of cerebrovascular diseases and no neuronal deficiency were enrolled as controls (mean age, 67±4 years). Test-retest intraclass correlations were 0.88, 0.75, 0.86, and 0.86 for CD34, CD133, CD117, and CD135,

respectively, obtained from 5 volunteers tested twice with an interval of at least 10 days between samples.

Univariate correlations were performed using Pearson's correlation coefficient and Spearman's correlation coefficient. Statistical comparisons among groups were determined using analysis of variance. Individual comparisons were performed using Student's *t* test. In all experiments, mean±SE is reported.

Results

First, we investigated mobilization of immature cells after acute cerebral infarction (n=5), focusing on CD34⁺ cells. The level of CD34⁺ cells gradually increased to day 7 and remained significantly above the prestroke baseline on days 7 and 14, returning to baseline levels by day 30 (Figure 2A). On the basis of these data, we enrolled 25 patients with a history of atherothrombotic cerebral ischemic events, excluding those who had suffered cerebrovascular or cardiovascular acute ischemic episodes in the 30 days before study, as well as premenopausal females. In this group (>30 days after stroke), no correlation was observed between the interval after stroke and the level of circulating CD34⁺ cells ($r=0.009$, $P=0.97$). Characteristics of this group included mean age of 68±2 years, 20 men and 5 women, 23 patients receiving antiplatelet therapy, 11 patients receiving antihypertensive therapy, 6 patients receiving therapy for hyperlipidemia, 5 patients receiving therapy for diabetes mellitus (DM), and 16 patients with a current or past history of smoking.

Several factors were found to influence the number of circulating CD34⁺ cells. Statistical analysis revealed a significant decrease in circulating CD34⁺ cells in patients with DM ($0.5±0.1$; non-DM, $1.2±0.1$ cells/ μ L; $P=0.01$). In contrast,




Figure 2. Levels of circulating CD34⁺ cells and stroke. Circulating CD34⁺ cells increased after the onset of stroke and peaked on day 7. A significant increase in circulating CD34⁺ cells was observed on days 7 and 14 (A). A decrease of circulating CD34⁺ cell was observed with aging in the control group (B), but no such correlation was observed in the stroke patient group (C). No correlation was observed between the number of circulating CD34⁺ cells and the degree of arteriosclerosis in major cerebral arteries (D). However, there was a correlation between cerebral infarctions and circulating CD34⁺ (E) and CD133⁺ cells (F). In contrast, there was no correlation between cerebral infarction and CD117⁺ (G) or CD135⁺ cells (H). Correlation between circulating CD34⁺ (I) and CD133⁺ (J) cells and CBF in areas of chronic hypoperfusion was observed. Lower levels of circulating CD34⁺ cells were correlated with a decrease in CMRO₂ (K) but not with a change in OEF (L). * $P < 0.05$ compared with day 0 (based on 2-way ANOVA).

no change was observed in patients with hypertension ($P = 0.61$), with hyperlipidemia ($P = 0.81$), with smoking ($P = 0.64$), or based on gender ($P = 0.36$). In addition, treatment with HMG-CoA reductase inhibitors ($P = 0.81$), compared with patients without hyperlipidemia, did not impact the number of CD34⁺ cells. In the control patient group, a decrease of circulating CD34⁺ cells was observed with aging (Figure 2B), although this was not observed in the patient group (Figure 2C). Comparing baseline levels of circulating CD34⁺ cells, there was a significant decrease in the patient group compared with age-matched controls (stroke, 1.1 ± 0.1 ; control, 1.6 ± 0.2 cells/ μ L; $P = 0.02$).

We sought a possible correlation between circulating immature cells and the degree of arteriosclerosis of the common and

internal carotid arteries in the patients with atherothrombotic cerebral ischemic events. However, there was no significant correlation between arteriosclerosis and circulating CD34⁺ (Figure 2D). This result was not surprising, because multiple risk factors and cell types contribute to progression of vascular lesions in major arteries. In contrast, because disruption of vascular homeostasis and repair are associated with cerebral infarction, we reasoned that a history of cerebral infarction might correlate with circulating immature cells. A strong correlation was observed between the number of infarcts and the absolute number of circulating CD34⁺ cells (Figure 2E) and CD133⁺ cells (Figure 2F). However, no significant correlation with regard to cerebral infarcts was observed with circulating CD117⁺ cells (Figure 2G) and CD135⁺ cells (Figure 2H).

In view of the critical role of endothelium in maintaining CBF, we evaluated cerebrovascular function in patients with chronic hypoperfusion. Direct correlations were observed between CBF (in the chronically hypoperfused area) and circulating CD34⁺ cells (Figure 2I) and CD133⁺ cells (Figure 2J). In addition, lower numbers of circulating CD34⁺ cells (Figure 2K) correlated with diminished CMRO₂, although there was no significant increase in the OEF (Figure 2L). These observations suggest a contribution of CD34⁺ cells in homeostasis and repair of the cerebral circulation and maintenance of brain metabolism. No correlation was observed with the above parameters of vascular function and circulating CD117⁺ and CD135⁺ cells. Measurement of angiogenic growth factors in patient plasma, vascular endothelial growth factor, basic fibroblast growth factor, hemopoietic growth factor, and insulin-like growth factor-1 also demonstrated no correlation with indices of cerebrovascular function or the number of CD34⁺ cells (not shown).

Discussion

We have found that circulating immature cell populations, especially CD34⁺ and CD133⁺ cells, are associated with maintenance and repair of the cerebral vasculature. In our study, we used a simple and precise method to count the absolute number of circulating CD34⁺ cells in a small sample of peripheral blood. Our results indicate that the level of CD34⁺ cells serves as an index/marker for cerebrovascular function. Analysis of CD133⁺, CD117⁺, and CD135⁺ cells, which identify other populations of immature cells, demonstrated that only CD133⁺ cells correlated with cerebrovascular function in a manner paralleling CD34⁺ cells.

Patients with diabetes displayed a significant reduction in the number of circulating CD34⁺ cells. In view of the microvascular dysfunction that is characteristic of diabetes, this may not be surprising. Similarly, decreased circulating CD34⁺ cells with increasing age in healthy individuals may be associated with limited vascular renewal in older individuals. It was also of interest to note no change between levels of CD34⁺ cells in patients taking HMG-CoA reductase inhibitors. The latter results might reflect the positive effect

of such drugs countering the negative effect of hyperlipidemia on circulating CD34⁺ cells. Such conclusions, of course, are at best tentative, because in this first report we have identified associations rather than proved a cause-effect relationship.

These observations suggest that diminished numbers of CD34⁺ and CD133⁺ cells impact maintenance and repair of cerebral vasculature. Precise measurement of circulating CD34⁺ cells provides a marker for cerebrovascular function in the setting of ischemic stress.

Acknowledgments

This work was supported by the Uehara, Takeda, Terumo Medical Foundations and KAKENHI (15590785). The sponsors of the study had no role in study design, data collection, data analysis, interpretation, or writing of the report.

References

1. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. *Science*. 1997;275:964–967.
2. Taguchi A, Ohtani M, Soma T, et al. Therapeutic angiogenesis by autologous bone-marrow transplantation in a general hospital setting. *Eur J Vasc Endovasc Surg*. 2003;25:276–278.
3. Tateishi-Yuyama E, Matsubara H, Murohara T, et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. *Lancet*. 2002;360:427–435.
4. Hamano K, Nishida M, Hirata K, et al. Local implantation of autologous bone marrow cells for therapeutic angiogenesis in patients with ischemic heart disease: clinical trial and preliminary results. *Jpn Circ J*. 2001;65:845–847.
5. Majka M, Janowska-Wieczorek A, Ratajczak J, et al. Numerous growth factors, cytokines, and chemokines are secreted by human CD34⁺ cells, myeloblasts, erythroblasts, and megakaryoblasts and regulate normal hematopoiesis in an autocrine/paracrine manner. *Blood*. 2001;97:3075–3085.
6. Beck H, Voswinckel R, Wagner S, et al. Participation of bone marrow-derived cells in long-term repair processes after experimental stroke. *J Cereb Blood Flow Metab*. 2003;23:709–717.
7. Sasaki T, Watanabe M, Nagai Y, et al. Association of plasma homocysteine concentration with atherosclerotic carotid plaques and lacunar infarction. *Stroke*. 2002;33:1493–1496.
8. Hirano T, Minematsu K, Hasegawa Y, et al. Acetazolamide reactivity on ¹²³I-IMP single photon emission computed tomography in patients with major cerebral artery occlusive disease: correlation with positron emission tomography parameters. *J Cereb Blood Flow Metab*. 1994;14:763–770.



Administration of CD34⁺ cells after stroke enhances neurogenesis via angiogenesis in a mouse model

Akihiko Taguchi,¹ Toshihiro Soma,² Hidekazu Tanaka,³ Takayoshi Kanda,⁴ Hiroyuki Nishimura,⁵ Hiroo Yoshikawa,⁵ Yoshitane Tsukamoto,⁶ Hiroyuki Iso,⁷ Yoshihiro Fujimori,⁸ David M. Stern,⁹ Hiroaki Naritomi,¹ and Tomohiro Matsuyama⁵

¹Department of Cerebrovascular Disease, National Cardiovascular Center, Osaka, Japan. ²Department of Hematology, Osaka Minami National Hospital, Osaka, Japan. ³Department of Pharmacology, Graduate School of Medicine, Osaka University, Osaka, Japan. ⁴Department of Gynecology, Osaka Minami National Hospital, Osaka, Japan. ⁵Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan. ⁶Department of Pathology, Osaka Medical Center for Cancer and Cardiovascular Disease, Osaka, Japan. ⁷Department of Psychology and ⁸Department of Hematology, Hyogo College of Medicine, Hyogo, Japan. ⁹Medical College of Georgia, Augusta, Georgia, USA.

Thrombo-occlusive cerebrovascular disease resulting in stroke and permanent neuronal loss is an important cause of morbidity and mortality. Because of the unique properties of cerebral vasculature and the limited reparative capability of neuronal tissue, it has been difficult to devise effective neuroprotective therapies in cerebral ischemia. Our results demonstrate that systemic administration of human cord blood-derived CD34⁺ cells to immunocompromised mice subjected to stroke 48 hours earlier induces neovascularization in the ischemic zone and provides a favorable environment for neuronal regeneration. Endogenous neurogenesis, suppressed by an antiangiogenic agent, is accelerated as a result of enhanced migration of neuronal progenitor cells to the damaged area, followed by their maturation and functional recovery. Our data suggest an essential role for CD34⁺ cells in promoting directly or indirectly an environment conducive to neovascularization of ischemic brain so that neuronal regeneration can proceed.

Introduction

Thrombo-occlusive atherosclerotic cardiovascular disease is a major cause of death and disability in developed countries. In the acute phase, therapeutic maneuvers include fibrinolytic therapy to restore blood flow to the ischemic site. In the longer term, formation of new blood vessels is necessary to fully supply tissue metabolic and functional requirements. Although it had been assumed that postnatal development of neovessels resulted only from outgrowth of pre-existing vasculature, it has become evident that circulating endothelial progenitor cells (EPCs), contained in a CD34⁺ cell population enriched in cord blood, have the capacity to participate in neovascularization of ischemic tissues (1, 2). Thus, a new strategy proposed for enhancing recovery due to ischemic stress is administration of EPCs to stimulate formation of neovasculature. In this context, recent reports have demonstrated that infusion of EPCs results in their incorporation into neovasculature at the ischemic site and limitation of tissue damage in animal models (3). Furthermore, human CD34⁺ cells were shown to secrete numerous angiogenic factors, including VEGF, HGF, and IGF-1 (4). On the basis of these observations, clinical trials of cell transplantation in hindlimb (5, 6) and cardiac ischemia (7) have been initiated with promising results.

Nonstandard abbreviations used: anterior cerebral artery (ACA); cerebral blood flow (CBF); chloromethylbenzamide (CM-Dil); doublecortin (DCX); endothelial progenitor cell (EPC); erythropoietin (EPO); fetal liver kinase-1 (Flk-1); high-power field (HPF); middle cerebral artery (MCA); neuronal progenitor cell (NPC); neuron-specific nuclear protein (NeuN); phycoerythrin (PE); polysialylated neuronal cell adhesion molecule (PSA-NCAM); subventricular zone (SVZ); 2,3,5-triphenyltetrazolium (TTC).


Conflict of interest: The authors have declared that no conflict of interest exists.

Citation for this article: *J. Clin. Invest.* 114:330–338 (2004). doi:10.1172/JCI200420622.

Stroke is another setting of occlusive thromboatherosclerotic disease in which acceleration of angiogenesis might be expected to enhance the outcome. Despite the improvement of poststroke neurological outcome by administration of human cord blood cells (8) or bone marrow-derived cells (9) (both potentially a rich sources of stem cells including CD34⁺ cells) in rodent models, few of the administered cells could be demonstrated in brain parenchyma expressing neuronal markers, raising a question as to the underlying mechanism. The results of our study demonstrate that systemic administration of human CD34⁺ cells to immunocompromised mice subjected to stroke 48 hours earlier accelerates neovascularization of the ischemic zone. Such a rich vascular environment, along with generation of other nurturing neuronal mediators by CD34⁺ cells, such as VEGF, FGF2, and IGF-1 (10–12), enhances subsequent neuronal regeneration; endogenous neurogenesis is accelerated as neuronal progenitors migrate to the damaged area, followed by their maturation and survival when CD34⁺ cells have stimulated the formation of increased vascular channels. In contrast, in the presence of an antiangiogenic agent, the beneficial effect of CD34⁺ cells was lost. Our results provide the first direct link between vasculogenesis and neurogenesis in the repair of ischemic brain lesions.

Results

Induction of stroke and proliferation of endothelial cells in situ. A reproducible model of stroke in the middle cerebral artery (MCA) cortex, sparing the striatum, was developed in SCID mice by permanent ligation of the M1 distal portion of the left MCA. Subsequent infusion of carbon black showed strongly decreased staining in the affected area. Nonviability of affected tissue was confirmed by 2,3,5-triphenyltetrazolium (TTC) staining. Values of cortical width index (see Methods section) were highly reproducible (~0.34–0.36)

**Figure 1**

Endothelial proliferation in situ after stroke. On days 1, 3, 7, and 14 after stroke, the number of proliferating cells (BrdU⁺) and proliferating endothelial cells (co-staining for BrdU and CD31) was determined in the left cortical area of 1–1.5 mm distal from the midline. (A) Immunohistological analysis of proliferating cells labeled with BrdU (green), anti-mouse CD31 IgG (red), and both (yellow). The number of cells visualized with BrdU (B) and the subpopulation BrdU⁺ cells also displaying mouse CD31 (i.e., double positives) (C) are shown. Ten HPFs were evaluated for each animal ($n = 6$ per group) by two investigators blinded to the experimental protocol. Note in C, cells displaying mouse CD31 are termed endothelial cells (ECs). Black bars, ipsilateral; white bars, contralateral. * $P < 0.05$ versus control. Scale bar: 30 μm .

over the 12-week experimental period. Survival in this stroke model was greater than 95%, and no seizures were observed.

To estimate the optimal time to administer human CD34⁺ cells, proliferation of endothelial cells in vasculature of the penumbral region (at the leading edge of viable tissue) was assessed by in vivo BrdU labeling. Sections were visualized with antibody to BrdU and mouse-specific antibody to CD31 by confocal microscopy. Cellular profiles co-staining for both markers were considered proliferating endothelial cells (Figure 1A). On days 1 and 3 after stroke, a subpopulation of BrdU⁺ cells also stained with mouse CD31, indicating an endothelial origin of this signal (Figure 1, B and C). By day 7, although endothelial proliferation continued, it had begun to decrease. In contrast, BrdU-labeled cells were present in a constant, small amount on the contralateral (nonstroke) side (Figure 1, B and C). These data indicated that administration of CD34⁺ cells on day 2 after stroke would buttress the endogenous proliferative component of the vascular response to cerebral ischemia.

Administration of CD34⁺ cells after stroke. Human CD34⁺ cells (95% pure CD34⁺ cells) isolated from human cord blood or control cells (CD34⁻ cells with <0.2% CD34⁺ cells, also from human cord blood) were administered intravenously via tail vein 48 hours after stroke. Analysis of cell surface markers revealed that $1.5\% \pm 0.1\%$ and $0.9\% \pm 0.1\%$ of the CD34⁺ cell population expressed the endothelial lineage markers fetal liver kinase-1 (Flk-1) (1) and P1H12 (13), respectively ($n = 4$). The effect of CD34⁺ cells was evident within 24 hours of their transplantation. Labeling vasculature by infusion of carbon black ink demonstrated neovasculature at the border of the MCA and anterior cerebral artery (ACA) cortex (staining with TTC demarcates viable and nonviable tissue) in animals treated with CD34⁺ cells (Figure 2, A and B), compared with those receiving CD34⁻ cells (Figure 2C) or PBS alone (Figure 2D). Determination of the angiographic score confirmed the impression of increased neovasculature in animals transplanted with CD34⁺ cells, compared with other groups (Figure 2E). To evaluate vascular activation in affected cerebral vessels, we used mouse-specific antibody to CD13, an antigen expressed by endothelial cells in angiogenic, but not quiescent, vasculature (14). Visualization of mouse CD13 in brain sections 24 hours after cell transplantation showed that cells bearing this activated endothelial marker were most evident in sections from mice treated with CD34⁺ (Figure 2F), compared with those receiving CD34⁻ cells (Figure 2G) or PBS (Figure 2H). Increased density of vasculature in the ischemic territory of animals treated with CD34⁺ cells translated to significantly enhanced cerebral blood flow (CBF) (Figure 2I).

To analyze the effect of subpopulations within the general CD34⁺ cell population, we compared the effect of poststroke transplantation of the same number of CD34⁺ cells (containing Flk-1⁻ and Flk-1⁺ cells) with CD34⁺/Flk-1⁻ cells on vascular activation and neovascularization. Brain tissue was examined 7 days after cell transplantation, because EPCs are known to incorporate into capillary walls at ischemic sites by this time point after the ischemic episode (2). FACS analysis confirmed that the CD34⁺/Flk-1⁻ population contained less than 0.1% Flk-1⁺ cells ($n = 4$). On the basis of CD13 staining (using the same mouse-specific antibody mentioned earlier), there was similar activation of endogenous endothelium after transplantation of either CD34⁺ cells (including both Flk-1⁻ and Flk-1⁺ subpopulations) and CD34⁺/Flk-1⁻ cells (not shown). Although neovasculature was observed at the border of the MCA and ACA cortex in animals treated with CD34⁺ cells (Figure 2J) and CD34⁺/Flk-1⁻ cells (Figure 2K), mice treated with CD34⁺ cells displayed increased neovascularization based on angiographic score (scores of 22 ± 3 and 13 ± 2 , for CD34⁺ and CD34⁺/Flk-1⁻ cells, respectively; $P < 0.05$, $n = 6$).

Transplantation of CD34⁺ cells and poststroke functional recovery. Stroke causes motor deficits and behavioral abnormalities (15). Dysfunction of the cortex is closely linked to disinhibition of behavior (16). Compared with sham-operated controls, mice that received CD34⁻ cells or PBS displayed significant behavioral abnormalities on day 90 after cell transplantation ($n = 12$, for each group). Rearing counts under lighted conditions were 8.4 ± 0.8 (PBS), 8.7 ± 0.5 (CD34⁻ cells), 4.2 ± 0.5 (CD34⁺ cells), and 3.0 ± 0.5 (sham-operated controls) for each of the groups. Counts of locomotion were 5.1 ± 0.4 (PBS), 5.0 ± 0.4 (CD34⁻ cells), 3.7 ± 0.4 (CD34⁺ cells), and 3.3 ± 0.4 (sham). ANOVA revealed hyperactivity with respect to both rearing ($P < 0.01$) and locomotion ($P < 0.01$) in the CD34⁻ cell- and PBS-treated groups, compared with sham-operated controls. In contrast, mice treated with CD34⁺ cells showed no significant hyperactivity compared with sham-operated controls ($P > 0.05$), and displayed significant improvement in both behavioral tests compared with animals that received PBS or CD34⁻ cells ($P < 0.05$). Mice treated with CD34⁻ cells or PBS after stroke showed loss of this “dark” response, with respect to rearing ($P > 0.05$) and locomotion ($P > 0.05$). In contrast, animals treated with CD34⁺ cells displayed the expected increase in rearing and locomotion in the darkness ($P < 0.01$).

Using another behavioral paradigm, excessive startle consequent to auditory stimulation was observed in poststroke animals treated with CD34⁻ cells and PBS. Startle amplitudes were 0.9 ± 0.1 volts (PBS), 0.8 ± 0.1 (CD34⁻ cells), 0.5 ± 0.1 (CD34⁺




Figure 2

Transplantation of CD34⁺ cells after stroke accelerates neovascularization. (A–D) Mice subjected to stroke received CD34⁺ cells (A and B), CD34⁻ cells (C), or PBS alone (D) on day 2. Animals were infused with carbon black ink and killed at 24 hours after cell transplantations. Sections were stained with TTC. Neovascularization was noted at the border zone between the ACA and MCA areas (arrowheads show microvessels), especially in animals treated with CD34⁺ cells compared with those receiving CD34⁻ cells or PBS alone. (E) An angiographic score for each experimental condition based on analysis of 6 mice per group. (F–H) Activated endothelial cells were observed with antibody specific for mouse CD13 in the ACA area. F: CD34⁺ cells; G: CD34⁻ cells; H: PBS. (I) CBF was measured in the MCA area just outside of the penumbra, and values in animals treated with CD34⁺ cells (black bars), CD34⁻ cells (gray bars), or PBS (white bars) were compared with values before cell transplantation at times corresponding to days 1, 7, and 14 after cell transplantation (*n* = 6 per group). Data shown are relative CBF versus day the measurement was performed. (J and K) Labeling vasculature by infusion of carbon black ink demonstrated neovasculture at the border of the MCA and ACA cortex in animals treated with CD34⁺ cells (J) and CD34⁺/Flk-1⁻ cells (K) on day 7 after cell transplantation. Scale bars: 0.5 mm (A) and 0.1 mm (B, F, and J). **P* < 0.05 versus PBS.

cells), and 0.4 ± 0.1 (sham) on day 90. ANOVA revealed hyperactivity in the CD34⁻ cell- and PBS-treated groups, compared with sham-operated controls (*P* < 0.05). In contrast, mice treated with CD34⁺ cells showed no significant hyperactivity compared with sham-operated controls (*P* > 0.05). Shortening of the latency period with fear conditioning was also observed in poststroke animals treated with CD34⁻ cells and PBS compared with sham-operated controls (*P* < 0.05). In contrast, mice treated with CD34⁺ cells showed no significant hyperactivity (*P* > 0.05). Similar behavioral abnormalities were also observed on day 35 after cell transplantation. Since ischemic injury in our stroke model was limited to the cortex (hippocampus and striatum were intact), it was not surprising that spatial learning (water maze testing) and passive avoidance remained unchanged and comparable in all groups when assessed 5 weeks after stroke (data not shown). Mice showed rapid recovery from focal motor deficits, and by day 16 after stroke no motor deficits were detected using a modified three-point scale (17) (data not shown).

Effect of poststroke CD34⁺ cell transplantation on endogenous neurogenesis and cortical expansion. These results suggested that cortical function and neoangiogenesis, potentially supporting integrity of the MCA cortex, might be better maintained in animals treated with CD34⁺

cells after stroke. Such maintenance of cortical integrity might reflect CD34⁺ cell-mediated enhancement of the survival of ischemic neurons or acceleration of endogenous neurogenesis. Representative brains from poststroke animals in each group (treated with PBS alone, CD34⁻ cells, or CD34⁺ cells) are shown in Figure 3, A–F. There was a prominent increase in cortical width index in animals receiving CD34⁺ cells at 14, 35, and 90 days after cell transplantation (Figure 3G). Thus, cortical expansion in animals treated with CD34⁺ cells was most likely to reflect the result of ongoing neurogenesis, rather than maintenance of the integrity of ischemic neurons from the time of induction of stroke.

Cell trace analysis with a fluorescent dye revealed that labeled transplanted CD34⁺ cells were not co-stained with antibody to a neuronal (neuron-specific nuclear protein; NeuN) or an astrocyte (glial fibrillary acidic protein) marker (not shown). However, activation of endogenous neurogenesis was observed after stroke, and this was accentuated in mice receiving CD34⁺ cells. On day 7 after administration of CD34⁺ cells, cells expressing the polysialylated neuronal cell adhesion molecule (PSA-NCAM), a marker of migrating neuronal progenitor cells (NPCs) (18), were observed in the subventricular zone (SVZ), and migration of these NPCs toward the ischemic zone was visualized on day 14 using markers




Figure 3 CD34⁺ cell transplantation induces cortical expansion after stroke. (A–F) On day 14 (A–C), and day 90 (D–F) after cell transplantation, the brains of mice were evaluated grossly. Compared with poststroke mice treated with PBS (A and D) or infused with CD34⁻ cells (B and E), animals transplanted with CD34⁺ cells (C and F) showed an increase in area occupied by the left cortex. (G) Cortical regeneration was induced by CD34⁺ cells transplantation: triangles, CD34⁺ cells; squares, CD34⁻ cells; diamonds, PBS. In each case, there were 6 animals per group. Scale bar: 2 mm (A). **P* < 0.05 versus PBS.

for PSA-NCAM (Figure 4, A and B, corresponding to lower and higher magnifications, respectively), as well as the neuronal stem cell marker, Musashi-1 (Figure 4C) (19). Expression of doublecortin (DCX), a marker of immature, or early, neurons (20), was principally restricted to NPCs close to the SVZ (Figure 4D). In contrast, expression of a neuronal cell marker, NeuN, was observed after cell migration from the SVZ and appeared as a signal of lower intensity compared with nearby mature neurons (Figure 4E). The situation was quite different on the contralateral side in poststroke animals treated with CD34⁺ cells; no such movement of precursors (PSA-NCAM⁺ cells) was observed (Figure 4F). Although migrating NPCs were also seen in poststroke animals treated with PBS (Figure 4G) and CD34⁻ cells, this finding was considerably magnified in mice receiving CD34⁺ cells (Figure 4H).

To investigate mechanisms underlying cortical expansion, immunohistological analysis was conducted to visualize PSA-NCAM, NeuN, and MAP-2. On day 14 after transplantation of CD34⁻ cells after stroke, mature cortical neurons displaying neuronal markers NeuN (Figure 5A) and MAP-2 (Figure 5B) were observed up to the periphery of the ischemic area, whereas only a thin layer of migrating PSA-NCAM⁺ NPCs was observed at the ischemic edge (Figure 5C). In contrast, transplantation of CD34⁺ cells after stroke expanded cortical areas displaying a low density of NeuN⁺ (Figure 5D) and MAP-2⁺ cells (Figure 5E) beyond the boundary demarcating mature neurons. Migration of NPCs into this expanded area was also observed by PSA-NCAM staining (Figure 5F).

Next, we investigated the fate of NPCs migrating from the SVZ to the ischemic area. Poststroke animals treated with CD34⁻ cells displayed many cells with TUNEL⁺ nuclei around the lower part of cortical ischemic edge (Figure 5G). In contrast, there were a minimal number of TUNEL⁺ nuclei observed in the same region in animals subject to transplantation of CD34⁺ cells after stroke (Figure

5, H and I). Thus, animals treated with CD34⁺ cells after stroke display migration and survival of NPCs, which eventually contribute to a population of more mature neurons.

To confirm this evidence of neurogenesis, animals transplanted with CD34⁺ cells, CD34⁻ cells, or PBS after stroke were infused with




Figure 4 CD34⁺ cell transplantation accelerates neuronal regeneration after stroke. (A and B) On day 14, animals receiving CD34⁺ cells after stroke displayed migration of NPCs toward the ischemic area by PSA-NCAM immunostaining. (C–E) Analysis of serial sections displayed expression of neuronal stem cell markers, Musashi-1 (C) and DCX (D). Note that expression of DCX was limited to the area proximal to the SVZ. PSA-NCAM⁺ NPCs also expressed NeuN (E). Small NeuN⁺ nuclei were observed in PSA-NCAM⁺ NPCs, whereas more intensely staining and larger nuclei represent mature neurons. (F) On day 14 on the contralateral side, PSA-NCAM⁺ NPCs were limited to the SVZ; that is, no migration of NPCs was observed. (G) Migration of NPCs with small NeuN⁺ nuclei toward cortex was observed in poststroke mice treated with PBS on day 14 after cell transplantation. (H) The average number of NPCs in the white matter at the lower left of the left cortex per HPF from 5 animals under each condition. Three sections were evaluated in each animal, and *n* = 5 per group. Arrowheads delineate individual NPCs or demarcate areas rich in NPCs. Scale bars: 1 mm (A), 0.2 mm (B and F), and 0.4 mm (G). **P* < 0.05 versus PBS.




Figure 5 Therapeutic neovascularization, due to CD34⁺ cell transplantation after stroke, enhances neurogenesis. (A–F) On day 14 after CD34⁻ cell transplantation, mature cortical neurons were observed up to the edge of the ischemic region displaying neuronal markers, NeuN (A) and MAP-2 (B), whereas only a thin layer of migrating PSA-NCAM⁺ NPCs was observed at the ischemic edge (C). In contrast, after transplantation of CD34⁺ cells, expanded cortical areas displaying a low density of NeuN⁺ (D) and MAP-2⁺ cells (E) were observed beyond the boundary demarcating mature neurons. Migration of NPCs into this expanded area was also observed by PSA-NCAM staining (F). (G–I) On day 14, TUNEL⁺ cells were visualized around the lower part of the expanded cortical area. Whereas massive cell death was observed in animals receiving CD34⁻ cell transplantation (G), the number of TUNEL⁺ profiles was strongly reduced in mice transplanted with CD34⁺ cells (H). (I) The average number of TUNEL⁺ cells per HPF. Three sections were evaluated in each animal; *n* = 5 per group. Arrowheads indicate the expanded cortical areas displaying a low density of indicated marker. Scale bars: 100 μm (A) and 50 μm (G). **P* < 0.05 for CD34⁺ versus CD34⁻ cell transplantation.

BrdU every second day for a total of 14 days and then killed. BrdU- and NeuN-bearing cell populations were visualized to determine if a group of neurons might be undergoing cell division. In animals treated with PBS alone (Figure 6A) or CD34⁻ cells (Figure 6B), double staining for BrdU and NeuN displayed little evidence of cells (i.e., nuclei) expressing both markers. Only in animals infused with CD34⁺ cells after stroke did we consistently observe double-labeled cell profiles with BrdU and NeuN to produce a merged image with cells displaying both markers (Figure 6C). Quantification of these results showed a significant increase in double-positive profiles (i.e., cells co-staining with antibody to BrdU and NeuN) in poststroke animals infused with CD34⁺ cells (Figure 6D). Consistent with these data, total neuronal counts (Figure 6E) from sections stained with NeuN in the left cortex 90 days after cell transplantation demonstrated a significant increase in the number of cells visualized in animals transplanted with CD34⁺ cells compared with those receiving CD34⁻ cells or PBS. In addition, vasculature was visualized in the ischemic zone of the forebrain of animals treated with CD34⁺ cells 90 days later using anti-mouse CD31 as a marker. A distinct vascular network was seen in the expanded cortex associated with neurogenesis after stroke (Figure 6F). Such vessels displayed a pattern quite distinct from that observed on the contralateral (nonischemic) side (Figure 6G). In these vessels on the ischemic side, some endothelial cells were

observed to express human CD31 antigen (Figure 6H). On day 90, mature MAP-2⁺ dendrites were observed in the expanded cortex of poststroke animals treated with CD34⁺ cells (data not shown). These data are consistent with the formation of a stable neovasculature to support regeneration of cortical neurons.

Inhibition and acceleration of angiogenesis by antiangiogenic and angiogenic agents. To investigate the hypothesis that neovascularization is essential to support endogenous neuronal regeneration, we used an antiangiogenic agent, Endostatin. The latter is known to inhibit proliferation of endothelial cells (21) and to have a direct inhibitory effect on EPCs (22). Mice were subjected to stroke, CD34⁻ or CD34⁺ cells were administered, and animals were divided into two groups; one group received Endostatin and the other PBS (*n* = 5, for each group). On day 7 after cell transplantation, treatment with Endostatin suppressed endothelial proliferation to 18% ± 3% and 22% ± 3% in mice transplanted with CD34⁻ cells and CD34⁺ cells, respectively, compared with proliferation observed in PBS-treated controls. Administration of Endostatin also impaired cortical expansion due to transplantation of CD34⁺ cells. On day 14, the cortical width index was 0.33 ± 0.01 and 0.41 ± 0.01 with and without Endostatin, respectively (*P* < 0.01). Animals treated with CD34⁺ cells and Endostatin after stroke displayed a reduction in migrating NPCs; 101 ± 7 cells per high-power field (HPF), for animals treated with CD34⁺ cells + PBS, and 21 ± 2 cells/HPF for animals treated with CD34⁺ cells + Endostatin (*P* < 0.01). Similarly, on day 14, the number of neurons in the post-stroke cortex was less in mice treated with CD34⁺ cells + Endostatin (1,469 ± 53), compared with animals treated with CD34⁺ cells + PBS (2,213 ± 36; *P* < 0.01).

To gain further support for our hypothesis, we used the proangiogenic agent erythropoietin (EPO). EPO, well known for its essential role in regulating proliferation and differentiation of erythroid cells, has recently been found to promote mobilization of EPCs (23) and to have angiogenic potential (24). On day 4 after stroke, a significant increase in circulating CD34⁺ cells was observed with EPO injection (5,244 ± 1,267 and 1,333 ± 389 cells/ml in the EPO and PBS groups, respectively; *n* = 6 per group, *P* < 0.05). In addition, mice treated with EPO displayed enhanced neovascularization based on angiographic score (5.4 ± 0.8 and 1.2 ± 0.4, in EPO and PBS groups, respectively; *n* = 5 per group, *P* < 0.05). On day 28 after stroke, treatment with EPO increased the number of cells co-staining for BrdU and NeuN (3.4 ± 0.3 and 0.4 ± 0.1/HPF in the EPO and PBS groups, respectively; *n* = 5 per group, *P* < 0.05). It should be noted that the magnitude of the stimulatory effect of EPO treatment on angiogenesis and neurogenesis in these experiments was less than that observed in studies with CD34⁺ cell transplantation, probably because of the greater number of cells transferred in the latter case.

Neurogenesis in 24-week-old mice. To analyze the effect of increased age on accelerated neurogenesis associated with CD34⁺ cell transplantation, 24-week-old SCID mice were used. Compared with poststroke mice treated with CD34⁻ cells (Figure 7A), transplantation of CD34⁺ cells (Figure 7B) showed a significant increase in area occupied by the left cortex on day 35 (Figure 7C). In addition,




Figure 6 Therapeutic neovascularization supports survival of regenerating neurons. (A–C) Animals treated with PBS alone (A), CD34⁻ cells (B), or CD34⁺ cells (C) were infused with BrdU, killed, and studied immunohistochemically with antibody to BrdU (red), NeuN (green), or both (yellow). (D) The average number of double-positive cells (stained with antibody to BrdU and NeuN) per HPF on day 90 after cell transplantation. Ten fields were evaluated in each animal, and *n* = 6 per group. **P* < 0.05 versus PBS. (E) On day 90 after cell transplantation, brain sections from animals treated with PBS alone, CD34⁻ cells, or CD34⁺ cells were stained with antibody to NeuN, and the number of total neurons in the left cortex was counted. (E) The average number of total NeuN⁺ cells in the left cortex. *n* = 6 per group; **P* < 0.05 versus PBS. (F and G) On day 90 after cell transplantation, mouse CD31 was visualized immunohistologically in forebrain sections from poststroke animals. Newly formed vascular networks were observed in the expanded cortex. The vascular pattern displayed by these neovessels on the ipsilateral (F, ischemic side) was different from that observed on the contralateral side (G). (H) On day 90, human CD31 was visualized immunohistologically. Human endothelial cells were observed in the regenerating cortex of animals treated with CD34⁺ cells after stroke. The arrowhead shows a human CD31⁺ endothelial cell. Scale bars: 50 μm (A), 100 μm (F and G), and 20 μm (H).

tion, evidence of vascular activation, as judged by reactivity with anti-CD13 antibody, was observed in mice treated with CD34⁺ cells (Figure 7D, CD34⁻ cells; Figure 7E, CD34⁺ cells). Migration of NPCs was observed in mice treated with CD34⁻ cells (Figure 7F) and CD34⁺ cells (Figure 7G), but a significant enhancement was observed in animals receiving CD34⁺ cells (Figure 7H). Only a thin layer of migrating PSA-NCAM⁺ NPCs was observed at the ischemic edge in animals treated with CD34⁻ cells (Figure 7I). In contrast, CD34⁺ cell transplantation resulted in a much thicker layer of PSA-NCAM⁺ cells (Figure 7J). Comparing these data in 24-week-old animals with our previous results using 5-week-old mice, the

older animals displayed a similar cortical width index (5 weeks old, 0.45 ± 0.01; 24 weeks old, 0.43 ± 0.02; *P* > 0.05), although older age was associated with a decrease in NPCs migrating into the cortex (5 weeks old, 71 ± 3 cells/HPF; 24 weeks old, 43 ± 4 cells/HPF; *P* < 0.05) on day 35 after CD34⁺ cell transplantation.

Discussion

Our findings show that administration of human CD34⁺ cells to immunocompromised mice 48 hours after stroke enhances neovascularization at the border of the ischemic zone followed by endogenous neurogenesis. Furthermore, suppression of the neo-




Figure 7 CD34⁺ cell transplantation in 24-week-old animals. (A–C) On day 35 after cell transplantation, the brains were evaluated. Compared with poststroke mice treated with CD34⁻ cells (A), animals transplanted with CD34⁺ cells (B) showed an increase in area occupied by the left cortex. Significant cortical regeneration was induced by CD34⁺ cells transplantation (C). (D and E) Compared with CD34⁻ cell transplantation (D), increased evidence of activated vasculature was observed in animals receiving CD34⁺ cells (E), as detected with mouse specific anti-CD13 antibody. (F–H) Migration of NPCs (small NeuN⁺ nuclei migrating toward the cortex) was observed in poststroke mice treated with CD34⁻ cells (F) and with CD34⁺ cells (G). However, a significant increase in migrating NPCs was induced by CD34⁺ cell transplantation (H). (I and J) A thin layer of migrating PSA-NCAM⁺ NPCs was observed at the ischemic edge of the cortex in animals treated with CD34⁻ cells (I), compared with a much thicker layer in those receiving CD34⁺ cells (J). Scale bars: 2 mm (A), 0.1 mm (D and I), and 0.4 mm (F). *n* = 4 in each group; **P* < 0.05 versus CD34⁻ cells.



vascularization by an antiangiogenic agent impaired neurogenesis. On the basis of these data, accelerated neovessel formation seems to be essential for enhancing endogenous neurogenesis and improving functional recovery.

The generation of new neurons in the adult is largely restricted to two regions: the SVZ lining the lateral ventricles and the subgranular zone of the dentate gyrus (25). In the transient cerebral ischemia model, evidence has been provided that neuronal regeneration occurs (10, 20). However, even in a transient ischemia model in which integrity of the microcirculation is maintained, it was shown that greater than 80% of newly formed neurons died, most likely because of unfavorable environmental conditions including lack of trophic support and exposure to products of damaged tissue. These considerations may underlie the observation that only 0.2% of nonviable ischemic neurons were replaced through neurogenesis (20). Such previous observations are consistent with our current results in animals treated with CD34⁺ cells or PBS, in which there was no enhancement of neovascularization, no neurogenesis, and no functional recovery.

Consistent with these data, Endostatin-mediated suppression of endothelial proliferation and direct effects on EPCs abrogated the beneficial effect CD34⁺ cells on neurogenesis and cortical expansion, and at the same time inhibited formation of neovasculature after stroke. In contrast, when EPO was used as a proangiogenic agent (recently, EPO has also been found to promote mobilization of EPCs) (23, 24), accelerated formation of neovasculature was accompanied by enhanced neurogenesis after stroke in our murine model. Our data provide the first direct link between therapeutic neovascularization after stroke and enhanced neurogenesis; formation of neovasculature after stroke supported neurogenesis. Consistent with a previous report (26), activation of NPCs after stroke was induced in adult, as well as young, murine brain. The number of activated NPCs was less in the adult animals, but a significant increase was still observed consequent to CD34⁺ cells transplantation, with evidence of activated vasculature in brains of the older animals. These findings support our hypothesis that administration of CD34⁺ cells provides a milieu favorable for neovascularization and endogenous neurogenesis, even in the mature brain.

A relationship between angiogenesis and neurogenesis would be consistent with regeneration of parenchymal cells in other organs subject to therapeutic angiogenesis (27, 28). Mechanisms underlying this observation might include more optimal preparation of the ischemic tissue bed for neuronal regeneration by accelerated removal of debris and toxic products, and/or the enhanced production of chemokines and trophic agents by neovasculature. Factors involved might be FGF2 (11), PDGF (29), brain-derived neurotrophic factor (30), and IL-8 (31), which have the capacity to induce mitogenesis, differentiation, recruitment, and survival of NPCs and newly generated neurons. In addition, mediators produced by CD34⁺ cells (4), such as VEGF, FGF2, and IGF-1, have been shown to accelerate endogenous neurogenesis (10–12). The effects of these and other factors derived from CD34⁺ cells (32, 33) acting on the vasculature are also likely to have an important role in providing an environment conducive to neurogenesis. Newly formed neurons in the setting of neovascularization have been shown to integrate into neuronal networks in adult animals (34); in fact, lack of participation of neurons in such neuronal circuits is probably associated with cell death (20). Our results provide strong support for the hypothesis that neovascularization consequent to administration of CD34⁺ cells induces neurogenesis by providing the necessary supportive environment. Whereas perturbation of the neurovascular unit has been proposed to contribute to tissue dam-

age in stroke, neovascularization and accompanying neurogenesis could be considered to be rebuilding crucial elements of the neurovascular unit (35). Previous reports have demonstrated that endothelial cells in newly formed vessels after stroke mainly originate from pre-existing endothelial cells (due to proliferation) with a contribution of circulating EPCs (36, 37). Consistent with these findings, we observed proliferating mouse endothelial cells around the ischemic area soon after stroke. The latter endothelial cells could be visualized, at least in part, with antibody specific for human CD31, after transplantation of human CD34⁺ cells. Furthermore, diminished neovascularization was observed after stroke following transplantation of CD34⁺/Flk-1⁻ cells, compared with CD34⁺ cells (containing both Flk-1⁻ and Flk-1⁺ cells) despite similar activation of murine endothelial cells in the ischemic territory in each case. These results support potential contribution of CD34⁺/Flk-1⁺ cells (a population known to be rich in EPCs) in expansion of the vascular network after stroke.

The actual pattern of the newly formed vascular network was quite different on the ipsilateral (ischemic) from the contralateral side in poststroke mice treated with CD34⁺ cells. This observation suggests that formation of vasculature consequent to transplantation of CD34⁺ cells after stroke does not simply reconstitute the original vascular network. Rather, a new vascular pattern arises (a true neovasculature) that is capable of supporting neurogenesis, followed by functional recovery, even though it displays a relatively “aberrant” pattern, at least anatomically, compared with the contralateral vasculature.

Our observations provide evidence of a crucial role for neovessel formation, achieved through the administration of CD34⁺ cells after stroke, in processes that underlie neurogenesis. These data strongly suggest that neovascularization is essential for neuronal regeneration after stroke and that therapeutic neovascularization is a potentially effective means of enhancing functional recovery. Our observations might explain the mild therapeutic effect achieved by neuronal cell transplantation after stroke reported in humans (38). This leads to the hypothesis that therapeutic neovascularization may be required to achieve optimal “take” of transplanted neuronal precursors in the setting of ischemia. Although the current data bear most directly on the endogenous neuronal response to cerebrovascular ischemia, it is possible that enhanced formation of neovasculature may also be important for survival of embryonic (39) and neural (40) stem cell transplants in other circumstances, such as neurodegenerative disorders.

Methods

All procedures were done in accordance with the National Cardiovascular Center Animal Care and Use, and Human Assurance Committees. Quantitative measurements and behavioral tests were conducted by investigators blinded to the experimental protocol and identity of the sections and animals under study.

Induction of focal cerebral ischemia. Permanent focal cerebral infarction was produced by ligation and disconnection of the distal portion of the left MCA. Male SCID mice (5 weeks old; Oriental Yeast Co. Ltd., Tokyo, Japan) were used for experiments involving human cell transplantation. Male C57BL/6J mice (24 weeks old; Clea Japan Inc., Tokyo, Japan) were used for experiments with human recombinant EPO (Kirin, Tokyo, Japan). Under halothane inhalation (3%), the left MCA was isolated, electrocauterized, and disconnected just distal to its crossing of the olfactory tract (distal M1 portion). CBF in the MCA area was monitored as described (41). Mice that showed decreased CBF by approximately 75% immediately after and 24 hours after ligation were used for our experiments (success rate of >95%). Body temperature was maintained at 36.5–37°C using a heat lamp during



the operation and for 2 hours after MCA occlusion. The ratio of CBF after cell transplantation to CBF before cell transplantation was calculated to evaluate the change of CBF (termed relative CBF).

Analysis of perfusion and brain infarction after MCA occlusion. Carbon black ink (Fuekinori Kogyo Co. Ltd., Osaka, Japan) was used to delineate the perfused area after MCA ligation as described (42). Viability of brain tissue was evaluated using TTC (Sigma-Aldrich, St. Louis, Missouri, USA). Coronal sections (1 mm thick) of the forebrain were stained with 1% TTC, and the images of sections from the exact center of the forebrain were captured using a microscopic digital camera system (Olympus, Tokyo, Japan). The width of viable cortex was determined by NIH image.

Administration of CD34⁺ cells after stroke. CD34⁺ cells (containing Flk-1⁺ and Flk-1⁻ cell populations) and CD34⁺/Flk-1⁻ cells were isolated from cord blood using a Direct CD34 Progenitor Cell Isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), CD34 Multisort kit (Miltenyi Biotec), and anti-Flk-1 antibody (Sigma-Aldrich), according to the manufacturers' protocols. CD34⁺ mononuclear cells were also collected for control experiments. In each case, cell populations were analyzed by FACS (BD Biosciences, San Jose, California, USA) using PerCP-conjugated anti-CD34 antibody (BD Biosciences), phycoerythrin-conjugated (PE-conjugated) anti-P1H12 antibody (BD Biosciences), and anti-Flk-1 antibody (Sigma-Aldrich) conjugated with FITC according to the manufacturer's protocol (Zenon Alexa Fluor; Molecular Probes Inc., Eugene, Oregon, USA). For labeling studies, cells were incubated with the fluorescent dye chloromethylbenzamido (CM-Dil; Molecular Probes Inc.). Forty-eight hours after stroke, 5×10^5 CD34⁺, CD34⁺/FLK-1⁻, CD34⁻ cells, or the same volume (100 μ l) of PBS were infused intravenously via the tail vein.

For the analysis of the effect of aging on neurogenesis, 24-week-old male SCID mice were used. Because of the known increased evidence of tumors, infection (for example, excess mucus in the eye), and elevated plasma immunoglobulins in older SCID mice, the presence of each of these conditions was also investigated. Mice with evidence of weight loss, tumors, infection, or elevated plasma immunoglobulins (> 10 μ g/ml) were excluded from further analysis.

Immunohistochemistry. Mice brains were removed and fixed in paraformaldehyde. Coronal sections (20 μ m) were prepared using a vibratome (Leica Microsystems Inc., Wetzlar, Germany). To assess cell proliferation and angiogenesis, fresh frozen sections (20 μ m) were prepared and fixed in acetone. Sections were subjected to immunohistochemistry with antibody to NeuN (Chemicon International, Temecula, California, USA), mouse-specific antibody to CD31 (BD Biosciences), human-specific antibody to CD31 (DAKO A/S, Glostrup, Denmark), mouse-specific antibody to CD13 (Santa Cruz Biotechnology, Santa Cruz, California, USA), and antibodies to MAP-2 (Sigma-Aldrich), human von Willebrand Factor (DAKO A/S), PSA-NCAM (Chemicon International), DCX (Chemicon International), Musashi-1 (19), TUNEL (Molecular Probes Inc.), or BrdU (Boehringer Ingelheim, Ingelheim, Germany).

Cell proliferation analysis. For assessment of cell proliferation in vivo, BrdU (Sigma-Aldrich) was administered intraperitoneally. In the case of endothelial cell proliferation, BrdU (200 mg/kg) was administered 24 hours before killing. For endogenous neurogenesis, 50 mg/kg of BrdU was injected every second day for a total of 14 days. Cells co-staining for BrdU and mouse-specific antibody to CD31 using confocal microscopy (Olympus) in HPFs ($\times 40$ of objective lens) were counted as proliferating endothelial cells. The cell population co-staining for BrdU and NeuN was counted as regenerating-proliferating neurons. For quantitative analysis, brain sections at the exact center of the forebrain were stained, and the left cortical area of 1 mm (or > 1 mm) distal from the midline was examined by two investigators blinded to the experimental protocol. In each case, 10 representative fields were evaluated before quantitative results were analyzed.

Assessment of angiogenesis. For assessment of angiogenesis at the border of MCA and ACA areas, carbon black perfusion was used to visualize the

vasculature and TTC staining to demarcate the border of viable and non-viable tissue. Semi-quantitative analysis of angiogenesis made use of the angiographic score and was calculated by a previously described method (43). Microscopic digital images were scanned into a computer (Olympus), and an overlay, composed of 50- μ m-diameter circles arranged in rows spaced 100 μ m apart, was superimposed on the image. The total number of grids intersecting the border zone containing a microvessel was counted. Mouse-specific antibody to CD13 was used to visualize 'activated' vasculature.

Assessment of ischemic brain damage and neurogenesis. For determination of the cortical width index, whole-brain images were captured using a microscopic digital camera system (Olympus). The width at the midpoint of the forebrain was measured, and the ratio of left width to right width was defined as the cortical width index. To quantify accelerated neurogenesis, three brain sections around the center of the forebrain on day 14 after cell transplantation were stained with NeuN or TUNEL. The number of small NeuN nuclei-positive cells in the white matter at lower left of the left cortex and the number of TUNEL⁺ cells around the lower part of ischemic cortical edge was counted in HPFs. For determining the number of neurons in the left cortex, brain sections of the exact center of the forebrain on day 90 were stained with NeuN, and the total number of NeuN⁺ cells was quantitated.

Behavioral analysis. To assess cortical function, mice were subjected to behavioral testing in the open-field task (44) on day 35 or 90 after cell transplantation. Auditory startling behavior was tested as described (45). To estimate learning activity, mice were tested by water maze test (46) and passive avoidance test (47). To exclude the contribution of physical deficits directly related to the operative procedure and induction of stroke, motor deficiencies were examined on days 9 and 16 after stroke. Neurological deficits were scored on a three-point modified scale as described (17). Body weight, monitored in each experimental group, displayed no significant differences (data not shown).

Inhibition and promotion of neovascularization. Inhibition of neovascularization was achieved by administering Endostatin (10 μ g; subcutaneous; Calbiochem-Novabiochem, Darmstadt, Germany) once daily for 14 days. To stimulate mobilization of EPCs originating in the host, EPO (1,000 μ g/kg) was injected subcutaneously 24, 48, and 72 hours after ischemia. Peripheral blood cells were analyzed using FITC-conjugated anti-mouse CD45 (BD Biosciences), PE-conjugated anti-mouse CD34 antibodies (BD Biosciences), and 7-amino-actinomycin D viability Dye (Beckman Coulter Inc., Marseille Cedex, France), as described (48), using counting beads (BD Biosciences) as an internal control.

Data analysis. In all experiments, mean \pm SE is reported. Statistical comparisons among groups were determined using one-way ANOVA. Where indicated, individual comparisons were performed using Student's *t* test.

Acknowledgments

Musashi-1 was generously provided by H. Okano at Keiou University in Japan. This work was partially supported by the Uehara, Takeda, and Terumo Medical Foundations, Grant-in-Aid for Scientific Research from the ministry of Education (15590785) and from the Ministry of Health, Labour, and Welfare (16C-7, H16-CK-004). We would like to thank Y. Kasahara, K. Obata, and Y. Okinaka for technical assistance.

Received for publication November 24, 2003, and accepted in revised form May 18, 2004.

Address correspondence to: Akihiko Taguchi, Department of Cerebrovascular Disease, National Cardiovascular Center, 5-7-1 Fujishiro-dai, Suita, Osaka 565-8565, Japan. Phone: 81-6-6833-5012; Fax: 81-6-6872-7485; E-mail: ataguchi@res.ncvc.go.jp.



1. Asahara, T., et al. 1997. Isolation of putative progenitor endothelial cells for angiogenesis. *Science*. 275:964-967.
2. Asahara, T., et al. 1999. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. *Circ. Res.* 85:221-228.
3. Kawamoto, A., et al. 2001. Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. *Circulation*. 103:634-637.
4. Majka, M., et al. 2001. Numerous growth factors, cytokines, and chemokines are secreted by human CD34⁺ cells, myeloblasts, erythroblasts, and megakaryoblasts and regulate normal hematopoiesis in an autocrine/paracrine manner. *Blood*. 97:3075-3085.
5. Taguchi, A., Ohtani, M., Soma, T., Watanabe, M., and Kinoshita, N. 2003. Therapeutic angiogenesis by autologous bone-marrow transplantation in a general hospital setting. *Eur. J. Vasc. Endovasc. Surg.* 25:276-278.
6. Tateishi-Yuyama, E., et al. 2002. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. *Lancet*. 360:427-435.
7. Hamano, K., et al. 2001. Local implantation of autologous bone marrow cells for therapeutic angiogenesis in patients with ischemic heart disease: clinical trial and preliminary results. *Jpn. Circ. J.* 65:845-847.
8. Chen, J., et al. 2001. Intravenous administration of human umbilical cord blood reduces behavioral deficits after stroke in rats. *Stroke*. 32:2682-2688.
9. Hess, D.C., et al. 2002. Bone marrow as a source of endothelial cells and NeuN-expressing cells after stroke. *Stroke*. 33:1362-1368.
10. Nakatomi, H., et al. 2002. Regeneration of hippocampal pyramidal neurons after ischemic brain injury by recruitment of endogenous neural progenitors. *Cell*. 110:429-441.
11. Drago, J., Murphy, M., Carroll, S.M., Harvey, R.P., and Bartlett, P.F. 1991. Fibroblast growth factor-mediated proliferation of central nervous system precursors depends on endogenous production of insulin-like growth factor I. *Proc. Natl. Acad. Sci. U. S. A.* 88:2199-2203.
12. Jin, K., et al. 2002. Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. *Proc. Natl. Acad. Sci. U. S. A.* 99:11946-11950.
13. Solovey, A., et al. 1997. Circulating activated endothelial cells in sickle cell anemia. *N. Engl. J. Med.* 337:1584-1590.
14. Bhagwar, S.V., Petrovic, N., Okamoto, Y., and Shapiro, L.H. 2003. The angiogenic regulator CD13/APN is a transcriptional target of Ras signaling pathways in endothelial morphogenesis. *Blood*. 101:1818-1826.
15. Van Dam, D., et al. 2003. Age-dependent cognitive decline in the APP23 model precedes amyloid deposition. *Eur. J. Neurosci.* 17:388-396.
16. Farkas, T., et al. 2003. Peripheral nerve injury influences the disinhibition induced by focal ischaemia in the rat motor cortex. *Neurosci. Lett.* 342:49-52.
17. Tamatani, M., et al. 2001. ORP150 protects against hypoxia/ischemia-induced neuronal death. *Nat. Med.* 7:317-323.
18. Iwai, M., et al. 2003. Temporal profile of stem cell division, migration, and differentiation from subventricular zone to olfactory bulb after transient forebrain ischemia in gerbils. *J. Cereb. Blood Flow Metab.* 23:331-341.
19. Sakakibara, S., et al. 1996. Mouse-Musashi-1, a neural RNA-binding protein highly enriched in the mammalian CNS stem cell. *Dev. Biol.* 176:230-242.
20. Arvidsson, A., Collin, T., Kirik, D., Kokaia, Z., and Lindvall, O. 2002. Neuronal replacement from endogenous precursors in the adult brain after stroke. *Nat. Med.* 8:963-970.
21. O'Reilly, M.S., et al. 1997. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. *Cell*. 88:277-285.
22. Capillo, M., et al. 2003. Continuous infusion of endostatin inhibits differentiation, mobilization, and clonogenic potential of endothelial cell progenitors. *Clin. Cancer Res.* 9:377-382.
23. Bahlmann, F.H., et al. 2004. Erythropoietin regulates endothelial progenitor cells. *Blood*. 103:921-926.
24. Jaquet, K., Krause, K., Tawakol-Khodai, M., Geidel, S., and Kuck, K.H. 2002. Erythropoietin and VEGF exhibit equal angiogenic potential. *Microvasc. Res.* 64:326-333.
25. Gage, F.H. 2000. Mammalian neural stem cells. *Science*. 287:1433-1438.
26. Yagita, Y., et al. 2001. Neurogenesis by progenitor cells in the ischemic adult rat hippocampus. *Stroke*. 8:1890-1896.
27. Ross, M.A., Sander, C.M., Kleebl, T.B., Watkins, S.C., and Stolz, D.B. 2001. Spatiotemporal expression of angiogenesis growth factor receptors during the revascularization of regenerating rat liver. *Hepatology*. 34:1135-1148.
28. Toda, S., et al. 1999. Immunohistochemical expression of growth factors in subacute thyroiditis and their effects on thyroid folliculogenesis and angiogenesis in collagen gel matrix culture. *J. Pathol.* 188:415-422.
29. Johe, K.K., Hazel, T.G., Muller, T., Dugich-Djordjevic, M.M., and McKay, R.D. 1996. Single factors direct the differentiation of stem cells from the fetal and adult central nervous system. *Genes Dev.* 10:3129-3140.
30. Leventhal, C., Rafii, S., Rafii, D., Shahar, A., and Goldman, S.A. 1999. Endothelial trophic support of neuronal production and recruitment from the adult mammalian subependyma. *Mol. Cell. Neurosci.* 13:450-464.
31. Araujo, D.M., and Cotman, C.W. 1993. Trophic effects of interleukin-4, -7 and -8 on hippocampal neuronal cultures: potential involvement of glial-derived factors. *Brain Res.* 600:49-55.
32. Valable, S., et al. 2003. Angiotensin-1-induced PI3-kinase activation prevents neuronal apoptosis. *FASEB J.* 17:443-445.
33. Sun, W., Funakoshi, H., and Nakamura, T. 2002. Localization and functional role of hepatocyte growth factor (HGF) and its receptor c-met in the rat developing cerebral cortex. *Brain Res. Mol. Brain Res.* 103:36-48.
34. Louissaint, A., Jr., Rao, S., Leventhal, C., and Goldman, S.A. 2002. Coordinated interaction of neurogenesis and angiogenesis in the adult songbird brain. *Neuron*. 34:945-960.
35. Lo, E.H., Dalkara, T., and Moskowitz, M.A. 2003. Mechanisms, challenges and opportunities in stroke. *Nat. Rev. Neurosci.* 4:399-415.
36. Beck, H., et al. 2003. Participation of bone marrow-derived cells in long-term repair processes after experimental stroke. *J. Cereb. Blood Flow Metab.* 23:709-717.
37. Zhang, Z.G., Zhang, L., Jiang, Q., and Chopp, M. 2002. Bone marrow-derived endothelial progenitor cells participate in cerebral neovascularization after focal cerebral ischemia in the adult mouse. *Circ. Res.* 90:284-288.
38. Kondziolka, D., et al. 2000. Transplantation of cultured human neuronal cells for patients with stroke. *Neurology*. 55:565-569.
39. Hoehn, M., et al. 2002. Monitoring of implanted stem cell migration in vivo: a highly resolved in vivo magnetic resonance imaging investigation of experimental stroke in rat. *Proc. Natl. Acad. Sci. U. S. A.* 99:16267-16272.
40. Abe, K. 2000. Therapeutic potential of neurotrophic factors and neural stem cells against ischemic brain injury. *J. Cereb. Blood Flow Metab.* 20:1393-1408.
41. Matsushita, K., et al. 1998. Marked, sustained expression of a novel 150-kDa oxygen-regulated stress protein, in severely ischemic mouse neurons. *Brain Res. Mol. Brain Res.* 60:98-106.
42. Matsuyama, T., et al. 1983. Why are infant gerbils more resistant than adults to cerebral infarction after carotid ligation? *J. Cereb. Blood Flow Metab.* 3:381-385.
43. Takeshita, S., et al. 1994. Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. *J. Clin. Invest.* 93:662-670.
44. Kimble, D.P. 1968. Hippocampus and internal inhibition. *Psychol. Bull.* 70:285-295.
45. Sasaki, H., Iso, H., Coffey, P., Inoue, T., and Fukuda, Y. 1998. Prepulse facilitation of auditory startle response in hamsters. *Neurosci. Lett.* 248:117-120.
46. Balschun, D., et al. 2003. Does cAMP response element-binding protein have a pivotal role in hippocampal synaptic plasticity and hippocampus-dependent memory? *J. Neurosci.* 23:6304-6314.
47. Mereu, G., et al. 2003. Prenatal exposure to a cannabinoid agonist produces memory deficits linked to dysfunction in hippocampal long-term potentiation and glutamate release. *Proc. Natl. Acad. Sci. U. S. A.* 100:4915-4920.
48. Gratama, J.W., et al. 1999. Comparison of single- and dual-platform assay formats for CD34⁺ haematopoietic progenitor cell enumeration. *Clin. Lab. Haematol.* 21:337-346.

Relations of Serum High-Sensitivity C-Reactive Protein and Interleukin-6 Levels With Silent Brain Infarction

Taku Hoshi, MD; Kazuo Kitagawa, MD, PhD; Hiroshi Yamagami, MD, PhD;
Shigetaka Furukado, MD; Hidetaka Hougaku, MD, PhD; Masatsugu Hori, MD, PhD

Background and Purpose—Small silent brain infarction (SBI) is often found on magnetic resonance (MR) images of apparently healthy individuals at cardiovascular risk. Particularly, small SBI found in subcortical white matter, basal ganglia, or thalamus is thought to be caused by cerebral small vessel disease. Although several lines of evidence suggest a role of inflammatory processes in atherothrombotic vascular events, their involvement in SBI remains to be determined. This study examines the associations between serum inflammatory markers and SBI as a manifestation of cerebral small vessel disease.

Methods—One hundred ninety-four patients without histories of cardiovascular accidents were prospectively enrolled for this study. All patients underwent brain MR imaging and carotid ultrasonography, and patients with SBI diagnosed underwent further MR angiography. As common inflammatory markers, serum levels of high-sensitivity C-reactive protein (hsCRP) and interleukin-6 (IL-6) were evaluated.

Results—SBIs were found in 40 patients, and all of those were located in subcortical and infratentorial area, without MR angiographic evidence for obstructive lesions in proximal cerebral arteries. Mean hsCRP and IL-6 levels were higher in patients with SBI than in those without. Also, higher levels of both hsCRP (odds ratio [OR], 1.85 per standard deviation [SD] increase) and IL-6 (OR, 2.00/SD increase) were associated with higher likelihood for SBI. Moreover, the associations were only slightly attenuated when adjusting traditional cardiovascular risk factors and carotid IMT.

Conclusions—Higher levels of hsCRP and IL-6 appear to be associated with small SBI, suggesting a role of inflammatory processes in cerebral small vessel disease. (*Stroke*. 2005;36:768-772.)

Key Words: inflammation ■ interleukins ■ magnetic resonance imaging

Silent brain infarction (SBI), often seen on brain magnetic resonance (MR) images of healthy elderly individuals, is associated with increased risk for stroke and cognitive decline.¹ In previous studies, >90% of such SBIs were small (<15 mm in diameter) and found in subcortical white matter, basal ganglia, thalamus, or infratentorial region.²⁻⁵ Also, autopsy studies have shown that cerebral small vessel disease underlies such asymptomatic brain lesions.⁶⁻⁸ Although several risk factors have been identified for the occurrence of SBI, including age, hypertension, diabetes,^{5,9,10} homocysteine,¹¹⁻¹³ and carotid intima-media thickness,^{14,15} whether inflammatory processes are involved in its cause remains to be determined.

Recent studies in vascular biology have shown that chronic inflammation plays a crucial role in the development of atherosclerosis.¹⁶ Particularly, several lines of evidence suggest the value of measuring serum levels of inflammatory markers, such as high-sensitivity C-reactive protein (hsCRP) and interleukin-6 (IL-6), for predicting stroke and other cardiovascular events.¹⁷⁻²⁰ Additionally, such inflammatory

markers have been associated with plaque progression and its instability in large arteries.^{21,22} However, we are unaware of studies investigating the involvement of inflammation in SBI.

In the current study, we examine the associations of hsCRP and IL-6 with SBI in neurologically asymptomatic patients at cardiovascular risk to explore the relationships between inflammation and cerebral small vessel disease.

Patients and Methods

Patients

The subjects for this study were enrolled from neurologically asymptomatic patients who consecutively visited the Department of Internal Medicine and Therapeutics at Osaka University Hospital between April 2002 and December 2003. The majority of patients had been referred from another hospital or department for the risk assessment and primary prevention of stroke. At the time of referral, comprehensive neurological evaluations were performed by our stroke neurologists, including physical and psychological examinations. When no neurological signs/symptoms were identified, patients were found to be candidates for this study. Thus, patients with histories of stroke or other neurological disease were not included in

Received August 12, 2004; final revision received December 13, 2004; accepted January 11, 2005.

From the Division of Stroke Medicine, Department of Internal Medicine and Therapeutics (A8), Osaka University Graduate School of Medicine, Osaka, Japan.

Correspondence to Taku Hoshi, MD, Division of Stroke Medicine, Department of Internal Medicine and Therapeutics (A8), Osaka University Graduate School of Medicine, 2-2 Ymada-oka, Suita, Osaka 565-0871, Japan. E-mail thoshi@medone.med.osaka-u.ac.jp

© 2005 American Heart Association, Inc.

Stroke is available at <http://www.strokeaha.org>

DOI: 10.1161/01.STR.0000158915.28329.51

the study sample. Additionally, patients who had ever experienced nonspecific neurological symptoms, such as dizziness, vertigo, headache, tinnitus, and syncope, were included, but only if the symptoms were not present at the time of neurological evaluations. Given the nature of study sample, many of the patients had cardiovascular risk factors, including hypertension, hyperlipidemia, and diabetes.

During the study period, 236 patients were found to be potential candidates for this study. However, patients with ischemic heart disease ($n=24$) or peripheral vascular disease ($n=7$) were excluded. Additionally, patients with collagen disease ($n=5$), malignant disease ($n=2$), or acute viral infection ($n=4$) were excluded, because such conditions could increase the levels of inflammatory markers, potentially modifying the relationships between inflammatory markers and SBI. Consequently, this study comprised 194 neurologically asymptomatic patients (mean \pm standard deviation age, 67.3 ± 7.5 years) who subsequently underwent brain MR imaging.

This study was approved by the Ethics Committee of Osaka University Graduate School of Medicine. All patients gave written informed consent before entry to the current study.

Diagnosis of SBI

All MR imaging was performed with 1.5-T Signa Horizon (GE Medical Systems) or 1.5-T Magnetom Vision (Siemens). The whole brain was scanned, and 20 axial images were produced; slice thickness was 5 mm and interslice gap was 2 mm. The imaging protocol consisted of a T2-weighted spin-echo (repetition time/echo time [TR/TE]=5000/130 ms), T1-weighted spin-echo (TR/TE=500/9 ms), and fluid-attenuated inversion-recovery (TR/TE=8000/155 ms, inversion time=2000 ms) imaging.

A single trained physician who was blinded to patients' clinical details evaluated the existence, location, and size of brain infarcts on MR images. Thereby, SBI was defined as an area of focal hyperintensity on T2-weighted images with corresponding low signal intensity on T1-weighted images, which was ≥ 3 mm in diameter. Also, the diagnosis was made only when such a lesion was surrounded by hyperintense gliotic rim on fluid-attenuated inversion-recovery images to exclude dilated perivascular space.

When patients had SBI diagnosed, they subsequently underwent MR angiography to explore the existence of large vessel disease that could explain the cause of SBI.

Measurement of Serum Inflammatory Markers

After MR examination, blood was drawn with minimally traumatic venipuncture for measurement of serum inflammatory markers. Blood was then centrifuged at 3000 rpm at 4°C for 15 minutes, and aliquots were stored at -70°C. Circulating hsCRP was measured by latex turbidimetric immunoassay with a sensitivity of 0.01 mg/dL (Shionogi Biomedical Laboratory Inc). Serum IL-6 was measured by enzyme-linked immunosorbent assay (High Sensitivity Quantikine kit; R&D System). The detectable limit for IL-6 was 0.10 pg/mL.

Evaluation of Cardiovascular Risk Factors

Supine blood pressure was measured before the MR imaging examination. Fasting blood glucose, serum total cholesterol, high-density lipoprotein cholesterol, triglycerides, and serum creatinine levels were determined from the blood sample taken for inflammatory marker evaluation. Information on patient medical history and medication use was obtained from the clinical records, with investigators blinded to the MR findings. Hypertension was defined by casual blood pressure $\geq 140/90$ mm Hg or by current use of antihypertensive agents. Diabetes mellitus was defined by fasting blood glucose level ≥ 7.0 mmol/L or by use of glucose-lowering agents. Hyperlipidemia was defined by fasting serum total cholesterol level > 5.7 mmol/L, triglycerides level > 1.7 mmol/L, or by use of cholesterol-lowering agents. Smoking status was evaluated based on self-reports. Patients were categorized according to their smoking habits as nonsmoker (never smoked) or ever-smoker (smoked habitually at some time in their lives).

Evaluation of Carotid Atherosclerosis

Duplex carotid ultrasonography was performed to evaluate the severity of carotid atherosclerosis. All ultrasound examinations were performed with a Phillips SONOS 5500 equipped with a 7.5-MHz linear-array transducer. The intima-media thickness (IMT), defined as the distance between the intimal-luminal interface and the medial-adventitial interface, was measured as previously described.²³ We calculated the mean carotid artery IMT (mean IMT) by averaging the thickness at 12 sites: the near and far walls of both the right and left distal common carotid artery, carotid bifurcation, and internal carotid artery.

Statistical Analyses

Because the distributions of hsCRP and IL-6 levels appeared to be left-skewed, they were normalized by logarithmic transformation. To analyze the associations between inflammatory markers and patient characteristics, we used Pearson correlation analysis and 2-sample *t* test. To compare prevalence of SBI by the tertile of hsCRP and IL-6, we used χ^2 test. To analyze the relation between SBI and patient characteristics, we used χ^2 test for categorical data and 2-sample *t* test for continuous data. Odds ratio was calculated for the likelihood of SBI by multivariate logistic regression analyses, in which logarithmically transformed values of inflammatory markers were used. Of note, odds ratio was shown per standard deviation in log (inflammatory marker) increase. Probability values were 2-tailed, and values of $P < 0.05$ were considered significant. All statistical analyses were performed with SPSS 11.5J (SPSS Japan Inc).

Results

Patient Characteristics

Forty patients (21%) were found to have 1 or more SBIs on MR images (26 patients had a single infarct, whereas 14 had from 2 to 8 infarcts). Also, 50% of infarcts were located in the subcortical white matter (corona radiata, centrum semiovale, subcortical frontal, temporal and parietal lobes), and 45% were in the basal ganglia and thalamus (Figure 1). No patients had cortical infarcts in the study sample. Additionally, all infarcts ($n=72$) were < 15 mm in diameter, and 97% of those were < 10 mm. By MR angiographic examinations, 38 of 40 patients had no significant obstructive lesions in the proximal cerebral arteries. Although 2 patients had stenotic lesions (50% to 75%) in the horizontal portion of middle cerebral arteries, they were on the contralateral side to SBI.

Relation Between SBI and Inflammatory Markers

By univariate analysis, age, BMI, prevalence of hypertension, and systolic blood pressure were higher in patients with SBI than in those without, and so were hsCRP and IL-6 levels (Table 1). Additionally, prevalence of SBI was higher in the highest tertile of hsCRP level than in the lowest or middle tertile (Figure 2). Also, the prevalence was higher in the middle and highest tertiles of IL-6 level than in the lowest tertile.

Associations between inflammatory markers levels and SBI are summarized in Table 2. In unadjusted analysis, each 1 SD greater log hsCRP and each 1 SD greater log IL-6 were associated with 1.85-fold and 2.00-fold higher likelihood for SBI, respectively. Adjustments for age and sex modified these associations only slightly (model 1). After additional adjustments for traditional cardiovascular risk factor and medication use (model 2), both hsCRP and IL-6 remained to be associated with SBI. After further adjustments for mean IMT (model 3), these associations persisted.




Figure 1. Distribution of infarct location and size in patients with silent brain infarct on MR imaging.

Discussion

Recently, SBI has attracted much attention because it increases the risk for future stroke¹ and dementia.^{2,4} In the present study, levels of hsCRP and IL-6 were higher in patients with SBI than

in those without. Also, higher levels of such markers were associated with higher likelihood for SBI. To the best of our knowledge, this is the first study that demonstrates the associations between inflammatory markers and SBI.

TABLE 1. Baseline Characteristics of Patients With and Without Silent Brain Infarction

Index	All Patients (n=194)	Silent Brain Infarction		P Value
		No (n=154)	Yes (n=40)	
Age, y	67.3±7.5	66.5±7.6	70.6±6.0	0.002
Male sex, no. (%)	93 (48)	69 (45)	24 (60)	0.087
BMI, kg/m ²	23.0±2.7	22.8±2.6	23.8±3.3	0.03
Hypertension, no. (%)	128 (66)	94 (61)	34 (85)	0.004
Diabetes mellitus, no. (%)	31 (16)	21 (14)	10 (25)	0.081
Hyperlipidemia, no. (%)	130 (67)	101 (66)	29 (73)	0.4
Atrial fibrillation, no. (%)	5 (3)	3 (2)	2 (5)	0.6
Ever smoker, no. (%)	78 (40)	59 (38)	19 (48)	0.3
Systolic blood pressure, mm Hg	137.3±15.0	135.3±14.6	145.1±14.4	<0.001
Diastolic blood pressure, mm Hg	81.4±10.0	81.3±10.0	81.8±9.9	0.7
Total cholesterol, mmol/L	5.50±0.83	5.54±0.85	5.41±0.75	0.3
HDL cholesterol, mmol/L	1.54±0.41	1.50±0.39	1.46±0.41	0.5
Triglyceride, mmol/L	1.45±0.67	1.44±0.68	1.31±0.56	0.3
Fasting blood glucose, mmol/L	5.63±1.02	5.58±1.02	5.79±1.03	0.3
Serum creatinine, mg/dL	0.80±0.40	0.76±0.24	0.95±0.73	0.1
Mean IMT, mm	0.99±0.24	0.97±0.23	1.05±0.26	0.054
Medication use, no. (%)	105 (54)	81 (53)	24 (60)	0.4
Inflammatory marker				
High-sensitivity CRP, mg/dL	0.13±0.42 (0.05)	0.08±1.69 (0.04)	0.33±0.86 (0.08)	0.004
Interleukin-6, pg/mL	2.08±3.57 (1.32)	1.67±1.96 (1.20)	3.63±6.69 (1.89)	<0.001
Mini-Mental State Examination	28.1±2.0	28.1±2.2	28.0±1.6	0.6

Values are unadjusted mean±SD (median) or no. of patients (percentage).

P values are χ^2 test for the categorical data, and 2 sample t test for the continuous data.

Medication use means the percentage of patients who are using at least one anti-inflammation agent; Aspirin, HMG-CoA reductase inhibitors, angiotensin converting enzyme-inhibitors and angiotensin receptor blockers.

*Statistical tests performed in logarithmically transformed variables.




Figure 2. Prevalence (%) of silent brain infarction (SBI) by tertile of high-sensitivity CRP (lowest, <0.03 mg/dL; middle, 0.03 to 0.07 mg/dL; highest, ≥0.08 mg/dL) (A), and interleukin-6 (lowest, <1.06 pg/mL; middle, 1.06 to 1.75 pg/mL; highest, ≥1.76 pg/mL) (B). *P computed by χ^2 analysis.

In previous studies, prevalence of SBI is reported to be 10.6% to 24.8% in apparently healthy individuals.^{1,2,9,10,12} In the current study, 21% (40 out of 194) patients were found to have SBI, which is not surprising when the nature of our study sample is taken into account. Also, 95% of SBIs were located in the subcortical white matter, basal ganglia, or thalamus, and 97% of those were <10 mm (Figure 1). These findings are consistent with the commonly known features of SBI. Moreover, MR angiographic examinations revealed no significant obstructive lesions that could explain the occurrence of such SBI. Taken together, SBI found in this study is likely to be the manifestation of cerebral small vessel disease.

Previous studies have shown associations of SBI with age, hypertension, and diabetes.^{5,9,10} In line with such studies, age and prevalence of hypertension were higher in patients with SBI than in those without (Table 1). Also, hsCRP and IL-6 levels were higher in SBI patients than in those without (Table 1), suggesting an enhanced level of chronic inflammation in SBI patients. Moreover, prevalence of SBI increased in a stepwise fashion across the tertiles of hsCRP and IL-6 levels (Figure 2). Additionally, increases in such inflammatory markers were associated with higher likelihood for SBI (Table 2, model 1), and the associations persisted when traditional cardiovascular risk factors were adjusted (Table 2, model 2). These findings suggest the link between inflammation and SBI. Of note, recent studies have shown associations of SBI with carotid atherosclerosis.^{14,15} Given such studies, we have performed additional analysis with carotid IMT taken into account. When such parameters were included in the model (Table 2, model 3), the association between inflammatory markers and SBI were only slightly modified, further supporting their linkages.

Our findings suggest that inflammation is related to pathological changes in cerebral small vessels that cause lacunar

infarction. By measuring soluble plasma markers (eg, soluble intercellular adhesion molecule-1, soluble endothelial leukocyte adhesion molecule, and thrombomodulin), previous studies have shown inflammatory endothelial activation and endothelial dysfunction in patients with cerebral small vessel disease.^{25,26} Also, autopsy examinations revealed migration of foamy macrophages in the vessel walls of cerebral arterioles together with hyaline thickening and ectasia of parenchymal arteries in 15 out of 20 patients with ischemic vascular dementia.²⁷ These clinical and autopsy studies may support our result. In other words, although whether inflammatory endothelial activation induces arteriosclerosis and lipohyalinosis is not established, it is likely that chronic inflammatory response in cerebral small vessels is involved in the pathology of this microangiopathy.

This study has some limitations. First, because the current study is cross-sectionally designed, we cannot refer to the causal relationships between inflammatory markers and SBI. Second, recent studies have reported that elevated level of plasma homocysteine is associated with the risk factor for SBI,^{11-13,28} which could potentially impact on the relationships between inflammatory markers and SBI. Third, although SBI found in this study is likely to represent cerebral small vessel disease, possibility of cardiogenic or arteriogenic emboli cannot be completely denied. Taken together, extensive prospective studies are necessary to establish the link between inflammation and cerebral small vessel disease.

In conclusion, this study demonstrates that levels of circulating hsCRP and IL-6 are associated with SBI independent of traditional cardiovascular risk factors, suggesting an involvement of inflammation in cerebral small vessel disease.

TABLE 2. OR (95% CI) for The Prevalence of SBI According to Levels of Inflammatory Markers

	Multivariate Logistic Regression Analysis			
	Unadjusted OR (95% CI)	Model 1 OR (95% CI)	Model 2 OR (95% CI)	Model 3 OR (95% CI)
hsCRP, mg/dL per SD in log (hsCRP) increase	1.85 (1.29-2.63)	1.73 (1.20-2.51)	1.49 (1.00-2.22)	1.50 (1.00-2.24)
IL-6, pg/mL per SD in log (IL-6) increase	2.00 (1.39-2.88)	1.87 (1.29-2.71)	1.85 (1.24-2.78)	1.85 (1.24-2.78)

Model 1, adjusted for age and sex.

Model 2, adjusted for age, sex, BMI, smoking, hypertension, diabetes mellitus, hyperlipidemia and medication use.

Model 3, adjusted for age, sex, BMI, smoking, hypertension, diabetes mellitus, hyperlipidemia, medication use and mean IMT.

SD for log (hsCRP)=0.55; SD for log (IL-6)=0.30.

Acknowledgments


The present study was supported in part by the Smoking Research Foundation of Japan. We thank A. Kanzawa, M. Ikusawa, S. Imoto, and R. Morimoto for their secretarial assistance.

References

1. Vermeer SE, Hollander M, van Dijk EJ, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam scan study. *Stroke*. 2003;34:1126–1129.
2. Giele JL, Witkamp TD, Mali WP, van der Graaf Y. Silent brain infarcts in patients with manifest vascular disease. *Stroke*. 2004;35:742–746.
3. Kario K, Matsuo T, Kobayashi H, Hoshida S, Shimada K. Hyperinsulinemia and hemostatic abnormalities are associated with silent lacunar cerebral infarcts in elderly hypertensive subjects. *J Am Coll Cardiol*. 2001;37:871–877.
4. Hougaku H, Matsumoto M, Kitagawa K, Harada K, Oku N, Itoh T, Maeda H, Handa N, Kamada T. Silent cerebral infarction as a form of hypertensive target organ damage in the brain. *Hypertension*. 1992;20:816–820.
5. Vermeer SE, Den Heijer T, Koudstaal PJ, Oudkerk M, Hofman A, Breteler MM. Incidence and risk factors of silent brain infarcts in the population-based Rotterdam scan study. *Stroke*. 2003;34:392–396.
6. Fisher CM. The arterial lesions underlying lacunes. *Acta Neuropathol (Berl)*. 1968;12:1–15.
7. Tuszynski MH, Petito CK, Levy DE. Risk factors and clinical manifestations of pathologically verified lacunar infarctions. *Stroke*. 1989;20:990–999.
8. Shinkawa A, Ueda K, Kiyohara Y, Kato I, Sueishi K, Tsuneyoshi M, Fujishima M. Silent cerebral infarction in a community-based autopsy series in Japan. The hisayama study. *Stroke*. 1995;26:380–385.
9. Kobayashi S, Okada K, Koide H, Bokura H, Yamaguchi S. Subcortical silent brain infarction as a risk factor for clinical stroke. *Stroke*. 1997;28:1932–1939.
10. Longstreth WT, Jr., Bemick C, Manolio TA, Bryan N, Jungreis CA, Price TR. Lacunar infarcts defined by magnetic resonance imaging of 3660 elderly people: the cardiovascular health study. *Arch Neurol*. 1998;55:1217–1225.
11. Kim NK, Choi BO, Jung WS, Choi YJ, Choi KG. Hyperhomocysteinemia as an independent risk factor for silent brain infarction. *Neurology*. 2003;61:1595–1599.
12. Matsui T, Arai H, Yuzuriha T, Yao H, Miura M, Hashimoto S, Higuchi S, Matsushita S, Morikawa M, Kato A, Sasaki H. Elevated plasma homocysteine levels and risk of silent brain infarction in elderly people. *Stroke*. 2001;32:1116–1119.
13. Vermeer SE, van Dijk EJ, Koudstaal PJ, Oudkerk M, Hofman A, Clarke R, Breteler MM. Homocysteine, silent brain infarcts, and white matter lesions: the Rotterdam scan study. *Ann Neurol*. 2002;51:285–289.
14. Shinoda-Tagawa T, Yamasaki Y, Yoshida S, Kajimoto Y, Tsujino T, Hakui N, Matsumoto M, Hori M. A phosphodiesterase inhibitor, cilostazol, prevents the onset of silent brain infarction in Japanese subjects with type II diabetes. *Diabetologia*. 2002;45:188–194.
15. Kawamura T, Umemura T, Kanai A, Uno T, Matsumae H, Sano T, Sakamoto N, Sakakibara T, Nakamura J, Hotta N. The incidence and characteristics of silent cerebral infarction in elderly diabetic patients: association with serum-soluble adhesion molecules. *Diabetologia*. 1998;41:911–917.
16. Ross R. Atherosclerosis—an inflammatory disease. *N Engl J Med*. 1999;340:115–126.
17. Volpato S, Guralnik JM, Ferrucci L, Balfour J, Chaves P, Fried LP, Harris TB. Cardiovascular disease, interleukin-6, and risk of mortality in older women: the women's health and aging study. *Circulation*. 2001;103:947–953.
18. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. *N Engl J Med*. 1997;336:973–979.
19. Cesari M, Penninx BW, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrell K, Rubin SM, Ding J, Simonsick EM, Harris TB, Pahor M. Inflammatory markers and onset of cardiovascular events: results from the health ABC study. *Circulation*. 2003;108:2317–2322.
20. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. *Circulation*. 2000;101:1767–1772.
21. Hashimoto H, Kitagawa K, Hougaku H, Shimizu Y, Sakaguchi M, Nagai Y, Iyama S, Yamanishi H, Matsumoto M, Hori M. C-reactive protein is an independent predictor of the rate of increase in early carotid atherosclerosis. *Circulation*. 2001;104:63–67.
22. Yamagami H, Kitagawa K, Nagai Y, Hougaku H, Sakaguchi M, Kuwabara K, Kondo K, Masuyama T, Matsumoto M, Hori M. Higher levels of interleukin-6 are associated with lower echogenicity of carotid artery plaques. *Stroke*. 2004;35:677–681.
23. Sakaguchi M, Kitagawa K, Nagai Y, Yamagami H, Kondo K, Matsushita K, Oku N, Hougaku H, Ohtsuki T, Masuyama T, Matsumoto M, Hori M. Equivalence of plaque score and intima-media thickness of carotid ultrasonography for predicting severe coronary artery lesion. *Ultrasound Med Biol*. 2003;29:367–371.
24. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and the risk of dementia and cognitive decline. *N Engl J Med*. 2003;348:1215–1222.
25. Fassbender K, Bertsch T, Mielke O, Muhlhauser F, Hennerici M. Adhesion molecules in cerebrovascular diseases. Evidence for an inflammatory endothelial activation in cerebral large- and small-vessel disease. *Stroke*. 1999;30:1647–1650.
26. Hassan A, Hunt BJ, O'Sullivan M, Parmar K, Bamford JM, Briley D, Brown MM, Thomas DJ, Markus HS. Markers of endothelial dysfunction in lacunar infarction and ischaemic leukoariosis. *Brain*. 2003;126:424–432.
27. Vinters HV, Ellis WG, Zarow C, Zaias BW, Jagust WJ, Mack WJ, Chui HC. Neuropathologic substrates of ischemic vascular dementia. *J Neuropathol Exp Neurol*. 2000;59:931–945.
28. Hassan A, Hunt BJ, O'Sullivan M, Bell R, D'Souza R, Jeffery S, Bamford JM, Markus HS. Homocysteine is a risk factor for cerebral small vessel disease, acting via endothelial dysfunction. *Brain*. 2004;127:212–219.

Buerger病専門誌

—バージャー病治療と看護総覧—



茨城県バージャー病患者と家族の会

Buerger 病専門誌

Thromboangitis obliterans, TAO

—バージャー病治療と看護総覧—

目 次

目 次	2
はじめに	4
発刊に寄せて	茨城県議会議員 武藤 均 5
バージャー病の概論	筑波大学臨床医学系外科 榊原 謙 6
バージャー病の診察のポイント	自治医科大学循環器内科学 村上 善昭 8
バージャー病の内科治療のポイント	
	順天堂大学医学部循環器内科 加藤 洋一・代田 浩之 14
バージャー病の外科治療のポイント	筑波大学臨床医学系外科 佐藤 藤夫 18
バージャー病の看護のポイント	順天堂大学医学部附属順天堂医院看護部 戸島 郁子 20
自己幹細胞移植による血管再生療法	国立循環器病センター 田口 明彦 24
その他の新しい治療法 炭酸浴療法による血流改善	国立循環器病センター 田口 明彦 29
バージャー病に対する遺伝子治療	大阪大学医学部臨床遺伝子治療学教室 竹屋 泰 32
自己骨髄細胞移植による ～バージャー病における血管新生療法～	
	自治医科大学循環器内科学 村上 善昭 38
バージャー病患者さんの私記 不安と絶望が感謝から希望へ	福岡県 鴨井 大昌 50